Clinical Trial: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Brief Summary: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.

Detailed Summary: Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Sponsor: Gabrail Cancer Center Research

Current Primary Outcome: Overall Response Rate [ Time Frame: Every 8 weeks from screening until documented disease progression or date of death, whichever occurs first, up to approximately 100 months. ]

To evaluate the efficacy of single agent Selinexor in patients with poorly differentiated lung and gastroenteropancreatic (GEP) neuroendocrine tumors (NET) as determined by overall response rate (ORR) including complete (CR) and partial (PR) response.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Gabrail Cancer Center Research

Dates:
Date Received: August 21, 2014
Date Started: August 2014
Date Completion:
Last Updated: November 3, 2016
Last Verified: November 2016